Seven participants across two cohorts dosed in the Heart-2 Phase 1b clinical trial of VERVE-102 targeting PCSK9; Initial data planned for the first half of 2025 Dr. Kathiresan continued, “In addition, ...

Verve Therapeutics' stock remains a "Buy" despite recent setbacks, including the retirement of its Chief Medical Officer and the termination of a collaboration with Vertex. Verve's gene-editing ...

Shares of Verve Therapeutics (NASDAQ: VERV) were skyrocketing 75.7% higher as of 10:50 a.m. ET on Tuesday. And for good reason. Eli Lilly (NYSE: LLY) and Verve Therapeutics announced a "definitive ...

Verve Therapeutics grants equity awards to new employees as part of its stock incentive plan, promoting talent in genetic medicine development. Verve Therapeutics announced on June 2, 2025, that it ...

A single dose of VERVE-102 led to a 53% mean and 69% max LDL-C reduction at 0.6 mg/kg. No treatment-related SAEs or lab abnormalities were observed in 14 participants across three dose levels.

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Verve Therapeutics, a next-generation cardiovascular company developing therapies that safely edit the adult human genome to permanently reduce a person’s risk of ...

Verve Therapeutics (NASDAQ: VERV) stock is seeing explosive gains Tuesday. The biotech company's share price was up 24.5% as of 12:30 p.m. ET and had been up as much as 41% earlier in the session.

Initial data from the Heart-2 Phase 1b clinical trial of VERVE-102 targeting PCSK9 expected in the second quarter of 2025, with final dose escalation data in the second half of 2025 VERVE-102 has been ...

Reported positive initial data from the Heart-2 Phase 1b clinical trial of VERVE-102 demonstrating dose-dependent decreases in blood LDL-C and PCSK9 Mean reduction in LDL-C of 53%, with a maximum ...